Dr. Elizabeth Gerstner is a clinical neuro-oncologist at the Mass General Cancer Center. She obtained her bachelor's degree in neuroscience from Brown University and pursued her medical degree at Columbia University College of Physicians and Surgeons, where she served as Chief Resident in Neurology while completing her residency training. Dr. Gerstner then attended Harvard Medical School to earn her Masters in Medical Science.
Dr. Gerstner's research is focused on using neuro-imaging to probe tumor biology as well as determining how to incorporate promising imaging techniques into clinic trials. She has extensive experience working with clinical trials of new possible treatments of brain cancer and serves as the Primary Investigator (PI) or co-PI of two multi-institutional trials (American College of Radiology Imaging Network (ACRIN) 6684 and an Adult Brain Tumor Consortium trial) that incorporate advance MRI imaging to answer clinically and biologically relevant questions. In addition, Dr. Gerstner collaborates with a strong group of imaging researchers at Harvard's Martinos Center for Biomedical Imaging with expertise in analyzing the complex datasets generated through this research. She participates in the Quantitative Imaging Network, an NIH funded group looking to improve the role of quantitative imaging for clinical decision making in oncology by the development and validation of data acquisition, analysis methods, and tools to tailor treatment to individual patients and to predict or monitor the response to drug or radiation therapy.
Dr. Gerstner's research accomplishments have been recognized by a number of prestigious awards, including the Clinical Research Scholar, awarded by Massachusetts General Hospital Cancer Center and the Claflin Distinguished Scholar Award. She has been featured in many notable medical journals highlighting her research in collaboration with colleagues at Mass General and various physician-scientists from other prominent medical institutions.